Success Story: Turning Molecular Cancer Mechanisms Into National Interest, NIW Approval for a Research Fellow from China
Client’s Testimonial:
"I really appreciate your work on my NIW petition.”
On July 1st, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Research Fellow in the Field of Molecular Biology (Approval Notice).
General Field: Molecular Biology
Position at the Time of Case Filing: Research Fellow
Country of Origin: China
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: July 1st, 2026
Processing Time: 15 months, 17 days (Premium Processing Requested)
Case Summary:
The strength of this EB-2 National Interest Waiver (NIW) case came from translating highly specialized cancer biology into a clear national-interest argument. The client, a research fellow from China, was working on research that examined how breast cancer progressed at the cellular and molecular levels. USCIS approved the petition on July 1st, 2026, after 15 months and 7 days of processing, with Premium Processing requested on May 19th, 2026.
The client’s work focused on identifying novel molecular targets and clarifying the underlying mechanisms of cellular communication and genetic stability in aggressive malignancies. These biological pathways were critical because they dictated how diseased cells adapted, metastasized, and ultimately responded to targeted therapeutic interventions. North America Immigration Law Group (Chen Immigration Law Associates) emphasized that the client’s research was not simply an academic investigation of cancer cells, but part of a broader effort to improve the scientific foundation for future breast cancer therapies.
The evidentiary record showed that the client’s contributions had already gained meaningful recognition in the field. She held a Ph.D. in molecular and cell biology and had authored 7 peer-reviewed journal articles. Her work had received 313 citations, and 6 of her papers ranked among the top 10% most-cited articles in Molecular Biology and Genetics for their respective publication years. Her research had also received support from the National Cancer Institute, which reinforced its relevance to cancer-related scientific priorities.
The petition further demonstrated that independent researchers had actively relied on the client’s findings. Her work was utilized in subsequent studies involving disease progression, advanced targeted drug delivery, and systemic immune regulation. This evidence established that her research had entered broader scientific conversations, actively advancing downstream investigations in disease biology, therapeutic delivery methodologies, and molecular pathology.
With this approval, the client can continue advancing research that contributes to molecular biology, breast cancer therapeutic innovation, and improved cancer care, and we are pleased to have supported the presentation of her case.

